PRODUCT INFORMATION



O-desethyl Dapagliflozin

Item No. 36022

| CAS Registry No.: Formal Name: | 864070-37-1 (1S)-1,5-anhydro-1-C-[4-chloro-3-[(4- hydroxyphenyl)methyl]phenyl]-D-glucitol | OH |
|--|---|-------------|
| MF: | $C_{19}H_{21}CIO_6$ | O |
| FW: | 380.8 | |
| Purity: | ≥98% | ОН |
| Supplied as: | A crystalline solid | |
| Storage: | -20°C | U U OH |
| Stability: | ≥4 years | HO' V CI' V |
| Information represents the preduct exections. Datch execting and tight execute are previded on each certificate of an during | | |

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

O-desethyl Dapagliflozin is supplied as a crystalline solid. A stock solution may be made by dissolving the O-desethyl dapagliflozin in the solvent of choice, which should be purged with an inert gas. O-desethyl Dapagliflozin is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of O-desethyl dapagliflozin in these solvents is approximately 30 mg/ml.

O-desethyl Dapagliflozin is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, O-desethyl dapagliflozin should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. O-desethyl Dapagliflozin has a solubility of approximately 0.5 mg/ml in a 1:1 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one dav.

Description

O-desethyl Dapagliflozin is an inhibitor of sodium-glucose cotransporter 2 (SGLT2; $IC_{50} = 9.4 \text{ nM}$) and active metabolite of dapagliflozin (Item No. 11574).^{1,2} It is selective for SGLT2 over SGLT1 ($IC_{50} = 970 \text{ nM}$).¹

References

- 1. Xu, B., Feng, Y., Cheng, H., et al. C-aryl glucosides substituted at the 4'-position as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes. Bioorg. Med. Chem. Lett. 21(15), 4465-4470 (2011).
- 2. Xu, G., Lv, B., Roberge, J.Y., et al. Design, synthesis, and biological evaluation of deuterated C-aryl glycoside as a potent and long-acting renal sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 57(4), 1236-1251 (2014).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFFTY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

uyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/11/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM